Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy - Domchek, S M; Aghajanian, C; Shapira-Frommer, R; Schmutzler, R K; Audeh, M W; Friedlander, M (Gyn Onc, 2016)
, et al.